stoxline Quote Chart Rank Option Currency Glossary
  
Solid Biosciences Inc. (SLDB)
9.77  0.38 (4.05%)    03-01 16:00
Open: 9.53
High: 10.1
Volume: 129,227
  
Pre. Close: 9.39
Low: 9.335
Market Cap: 366(M)
Technical analysis
2024-03-01 4:55:15 PM
Short term     
Mid term     
Targets 6-month :  12.15 1-year :  14.2
Resists First :  10.4 Second :  12.15
Pivot price 9.36
Supports First :  7.31 Second :  5.4
MAs MA(5) :  9.63 MA(20) :  8.81
MA(100) :  5.27 MA(250) :  4.89
MACD MACD :  0.6 Signal :  0.7
%K %D K(14,3) :  74.2 D(3) :  77.3
RSI RSI(14): 60.7
52-week High :  10.4 Low :  1.8
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SLDB ] has closed below upper band by 37.3%. Bollinger Bands are 39% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.11 - 10.17 10.17 - 10.22
Low: 9.19 - 9.26 9.26 - 9.33
Close: 9.66 - 9.77 9.77 - 9.87
Company Description

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Headline News

Tue, 27 Feb 2024
Solid Biosciences (NASDAQ:SLDB) Stock Price Down 5.1% - MarketBeat

Sun, 25 Feb 2024
Head-To-Head Contrast: Graphite Bio (NASDAQ:GRPH) versus Solid Biosciences (NASDAQ:SLDB) - AmericanBankingNEWS

Wed, 17 Jan 2024
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up - Yahoo Finance

Tue, 16 Jan 2024
Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid (NASDAQ:SLDB) - Seeking Alpha

Mon, 15 Jan 2024
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why - Yahoo Finance

Sat, 09 Dec 2023
While institutions invested in Solid Biosciences Inc. (NASDAQ:SLDB) benefited from last week's 68% gain, private ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 37 (M)
Shares Float 10 (M)
Held by Insiders 0.6 (%)
Held by Institutions 77.1 (%)
Shares Short 428 (K)
Shares Short P.Month 248 (K)
Stock Financials
EPS 73.7
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.19
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -36 %
Return on Equity (ttm) -63.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.77
Qtrly Earnings Growth 0 %
Operating Cash Flow -108 (M)
Levered Free Cash Flow -61 (M)
Stock Valuations
PE Ratio 0.13
PEG Ratio 0
Price to Book value 1.35
Price to Sales 0
Price to Cash Flow -3.4
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android